Stem cell transplant: An experience from eastern India

Mukhopadhyay, A.; Gupta, P.; Basak, J.; Chakraborty, A.; Bhattacharyya, D.; Mukhopadhyay, S.; Roy, U. K.
October 2012
Indian Journal of Medical & Paediatric Oncology;Oct-Dec2012, Vol. 33 Issue 4, p203
Academic Journal
Background: Hematopoietic stem cell transplant using human leukocyte antigen (HLA)- matched sibling or unrelated bone marrow, or related or unrelated cord blood has been performed successfully to treat patients with different types of hematological malignancies, genetic disorders and hereditary immune deficiencies. Since 1983, stem cell transplantation has been carried out in different institutes of India. But, till then, no transplantation was performed in eastern India. Materials and Methods: Our present study is reporting for the first time stem cell transplantation in eastern India. From August 2000 to June 2011 (with a 3-year gap for up-gradation), we have performed a total of 22 transplants. Thirteen patients (M:F:9:4) with indications of aplastic anemia, thalassaemia, acute myeloid leukemia and chronic myeloid leukemia underwent allogenic transplant, whereas autologous transplant was performed for nine patients (M:F:2:1) of multiple myeloma, Hodgkin's and non-Hodgkin's lymphoma and neuroblastoma. The median age of the patients was 19.6 years, with a range of 5 years 8 months to 52 years. Fourteen patients received myeloablative conditioning regime whereas eight patients received immunosuppressive and less myeloablative protocol. Sources of stem cells in case of allogenic transplant are bone marrow and related or unrelated umbilical cord blood and in case of autologous transplant, these are peripheral blood stem cells or self-bone marrow. Standard prophylactic medication was followed prior to transplants. Results: A disease-free survival of 68.18% and overall survival of 86.3% were seen at the median follow-up period of 4.6 years. Common post-transplant complications were mucositis, infection, venoocclusive disease, graft versus host disease, hemorrhagic cystitis, etc. Conclusion: The use of cord blood as a source of stem cells has been proved inferior as compared with the bone marrow stem cell source in cases of thalassaemia in our institute and thus is not recommended for thalassaemia. But, it has been proved to be a very useful and effective stem cell source (both related and unrelated cord blood) in cases of aplastic anemia and other immunological disorders.


Related Articles

  • What Is the Most Appropriate Source for Hematopoietic Stem Cell Transplantation? Peripheral Stem Cell/Bone Marrow/Cord Blood. Demiriz, Itır Sirinoglu; Tekgunduz, Emre; Altuntas, Fevzi // Bone Marrow Research;2012, p1 

    The introduction of peripheral stem cell (PSC) and cord blood (CB) as an alternative to bone marrow (BM) recently has caused important changes on hematopoietic stem cell transplantation (HSCT) practice. According to the CIBMTR data, there has been a significant decrease in the use of bone marrow...

  • Fanconi anaemia: new strategies. Dufour, C.; Svahn, J. // Bone Marrow Transplantation;Jun2008 Supplement, Vol. 41, pS90 

    Fanconi anaemia (FA) is a rare genetic disease characterized by chromosomal instability, somatic abnormalities, marrow failure and cancer proness. The main cause of morbidity and mortality is bone marrow failure, which typically arises in the first decade of life and progresses to full-blown...

  • Autoimmune thyroid dysfunction after hematopoietic stem cell transplantation. Au, WY; Lie, AKW; Kung, AWC; Liang, R; Hawkins, BR; Kwong, YL // Bone Marrow Transplantation;Feb2005, Vol. 35 Issue 4, p383 

    Summary:Autoimmune thyroid disease (AITD) may occur in patients after hematopoietic stem cell transplantation (HSCT). In all, 10 cases of AITD (seven allogeneic and three autologous HSCT) were diagnosed among 721 HSCT recipients, including two patients with sequential hyper- and hypothyroidism....

  • Estimation of size of cord blood inventory based on high-resolution typing of HLAs. Song, E Y; Huh, J Y; Kim, S Y; Kim, T G; Oh, S; Yoon, J H; Roh, E Y; Park, M H; Kang, M S; Shin, S // Bone Marrow Transplantation;Jul2014, Vol. 49 Issue 7, p977 

    Methods for estimating the cord blood (CB) inventory size required vary according to the ethnic diversity of the HLA, degree of HLA matching and HLA-typing resolution. We estimated the CB inventory size required using 7190 stored CB units (CBU) and 2450 patients who were awaiting or underwent...

  • Umbilical cord blood banking: from personal donation to international public registries to global bioeconomy. Petrini, Carlo // Journal of Blood Medicine;2014, Vol. 6, p87 

    The procedures for collecting voluntarily and freely donated umbilical cord blood (UCB) units and processing them for use in transplants are extremely costly, and the capital flows thus generated form part of an increasingly pervasive global bioeconomy. To place the issue in perspective, this...

  • High-allelic variability in HLA-C mRNA expression: association with HLA-extended haplotypes. Bettens, F; Brunet, L; Tiercy, J-M // Genes & Immunity;Apr/May2014, Vol. 15 Issue 3, p176 

    Human leukocyte antigen (HLA)-C is a clinically relevant transplantation antigen in unrelated hematopoietic stem cell and cord blood transplantation. Furthermore, HLA-C antigens, as ligands for killer immunoglobulin-like receptors expressed on natural killer cells, have a central role in HIV...

  • An update to the HLA Nomenclature Guidelines of the World Marrow Donor Association, 2012. Bochtler, W; Maiers, M; Bakker, J N A; Baier, D M; Hofmann, J A; Pingel, J; Rist, H-G; Oudshoorn, M; Marsh, S G E; Müller, C R; Hurley, C K // Bone Marrow Transplantation;Nov2013, Vol. 48 Issue 11, p1387 

    For more than two decades, international cooperation and information technology have been playing key roles in the identification of suitable unrelated donors and cord blood units for hematopoietic SCT. To ensure consistent coding and interpretation of HLA data among the linked computer systems,...

  • Allogeneic hematopoietic cell transplantation from alternative sources for adult Philadelphia chromosome-negative ALL: what should we choose when no HLA-matched related donor is available? Nishiwaki, S; Atsuta, Y; Tanaka, J // Bone Marrow Transplantation;Nov2013, Vol. 48 Issue 11, p1369 

    The best outcome for patients with Ph chromosome-negative ALL (Ph(−) ALL) can be obtained by HLA-matched related donor (mRD) allogeneic hematopoietic cell transplantation (allo-HCT) in first CR. However, only 30% of patients have a mRD. Three alternative sources, unrelated donor (URD),...

  • Future perspectives. van Rood, J. J.; Goldman, J. M. // Bone Marrow Transplantation;May2010, Vol. 45 Issue 5, p843 

    In this article, the authors discuss the effectiveness of hematopoietic stem cells transplantation (HSCT) to treat patients with graft versus host disease (GVHD). They assert that the transplantation has human leukocyte antigens (HLA)-identical sibling donor which gives therapeutic modality to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics